Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: A 10-year institutional review

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Zehou, Ouidad ^a   Fabre, Elizabeth ^b   Zelek, Laurent ^c   Sbidian, Emilie ^a   Ortonne, Nicolas ^a   Banu, Eugeniu ^d   Wolkenstein, Pierre ^a   Valeyrie Allanore, Laurence ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c AVICENNE HOSPITAL   (France)

^d Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

Chemotherapy; Malignant peripheral nerve sheath tumor; Neurofibromatosis 1; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE; CARBOXYLIC ACID SALT; DOXORUBICIN; IFOSFAMIDE; INORGANIC SALT; PLATINUM SALT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; INSTITUTIONAL REVIEW; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUROFIBROMATOSIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84882475880     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-127     Document Type: Article

References (29)

1. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D, Jama 1997 278 1 51 57 10.1001/jama.1997.03550010065042 9207339 (Pubitemid 27274517)
2. Neurofibromatosis 1 phenotype associated to malignant peripheral nerve sheath tumours: a case-control study. Zehou O, Bularca S, Bastuji-Garin S, Ortonne N, Valeyrie-Allanore L, Wolkenstein P, Duong TA, J Eur Acad Dermatol Venereol 2013 27 8 1044 1047 10.1111/j.1468-3083.2012.04485.x 22348274
3. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, Baralle D, Br J Cancer 2006 95 2 233 238 10.1038/sj.bjc.6603227 16786042 (Pubitemid 44050923)
4. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Duong TA, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S, Glorion C, Lyonnet S, Zerah M, Kemlin I, et al. Orphanet J Rare Dis 2011 6 18 10.1186/1750-1172-6-18 21542925
5. A clinical study of type 1 neurofibromatosis in north west England. McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, Kingston H, Super M, Harris R, Evans DG, J Med Genet 1999 36 3 197 203 10204844 (Pubitemid 29110448)
6. Subclassification of nerve sheath tumors by gene expression profiling. Holtkamp N, Reuss DE, Atallah I, Kuban RJ, Hartmann C, Mautner VF, Frahm S, Friedrich RE, Algermissen B, Pham VA, et al. Brain Pathol 2004 14 3 258 264 15446580 (Pubitemid 39095987)
7. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A, J Med Genet 2002 39 5 311 314 10.1136/jmg.39.5.311 12011145 (Pubitemid 34526349)
8. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Ferner RE, Gutmann DH, Cancer Res 2002 62 5 1573 1577 11894862 (Pubitemid 34407825)
9. Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1. Valeyrie-Allanore L, Ismaili N, Bastuji-Garin S, Zeller J, Wechsler J, Revuz J, Wolkenstein P, Br J Dermatol 2005 153 1 79 82 10.1111/j.1365-2133.2005.06558.x 16029330 (Pubitemid 41044531)
10. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM, Cancer 1986 57 10 2006 2021 10.1002/1097-0142(19860515)57:10<2006::AID- CNCR2820571022>3.0.CO;2-6 3082508 (Pubitemid 16113778)
11. Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Kourea HP, Bilsky MH, Leung DH, Lewis JJ, Woodruff JM, Cancer 1998 82 11 2191 2203 10.1002/(SICI)1097-0142(19980601)82:11<2191::AID-CNCR14>3.0.CO;2-P 9610699 (Pubitemid 28240826)
12. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-Associated tumours. Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ, Sarcoma 2009 2009 756395 19360115
13. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Hruban RH, Shiu MH, Senie RT, Woodruff JM, Cancer 1990 66 6 1253 1265 10.1002/1097-0142(19900915)66:6<1253::AID- CNCR2820660627>3.0.CO;2-R 2119249 (Pubitemid 20310668)
14. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL, Int J Radiat Oncol Biol Phys 1998 42 2 351 360 10.1016/S0360-3016(98)00223-5 9788415 (Pubitemid 28502782)
15. Malignant schwannoma-clinical characteristics, survival, and response to therapy. Sordillo PP, Helson L, Hajdu SI, Magill GB, Kosloff C, Golbey RB, Beattie EJ, Cancer 1981 47 10 2503 2509 10.1002/1097-0142(19810515)47: 10<2503::AID-CNCR2820471033>3.0.CO;2-3 6791802 (Pubitemid 11127646)
16. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY, Ann Oncol 2009 20 Suppl 4 132 136 19454434
17. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, et al. J Clin Oncol 1997 15 1 350 362 8996162 (Pubitemid 27020593)
18. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Kolberg M, Holand M, Agesen TH, Brekke HR, Liestol K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA, Neuro Oncol 2013 15 2 135 147 10.1093/neuonc/nos287 23161774
19. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Lejeune FJ, Pujol N, Lienard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, et al. Eur J Surg Oncol 2000 26 7 669 678 10.1053/ejso.2000.0979 11078614
20. Soft-tissue sarcomas in adults. Clark MA, Fisher C, Judson I, Thomas JM, N Engl J Med 2005 353 7 701 711 10.1056/NEJMra041866 16107623 (Pubitemid 41175678)
21. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M, Cancer 2008 113 3 573 581 10.1002/cncr.23592 18521899
22. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline- containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T, J Clin Oncol 1999 17 1 150 157 10458228 (Pubitemid 29022388)
23. Neurofibromatosis type 1: from genotype to phenotype. Pasmant E, Vidaud M, Vidaud D, Wolkenstein P, J Med Genet 2012 49 8 483 489 10.1136/jmedgenet- 2012-100978 22889851
24. Recent developments in neurofibromatosis type 1. Lee MJ, Stephenson DA, Curr Opin Neurol 2007 20 2 135 141 10.1097/WCO.0b013e3280895da8 17351482 (Pubitemid 46411497)
25. Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Pasmant E, Masliah-Planchon J, Levy P, Laurendeau I, Ortonne N, Parfait B, Valeyrie-Allanore L, Leroy K, Wolkenstein P, Vidaud M, et al. Mol Med 2011 17 1-2 79 87 20844836
26. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, et al. Mol Cancer Ther 2009 8 5 1157 1168 10.1158/1535-7163.MCT- 08-1008 19417153
27. Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors. Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, et al. Clin Cancer Res 2013 19 2 450 461 10.1158/1078-0432.CCR-12-1067 23209032
28. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Agulnik M, Cancer 2012 118 6 1486 1497 10.1002/cncr.26361 21837674
29. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, et al. J Clin Invest 2013 123 1 340 347 10.1172/JCI60578 23221341